Top Markets
Coin of the day
AgeX Therapeutics, Inc. AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc.

AGE
株式のランク #28235
AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to... AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to pioneering and commercializing groundbreaking therapies that address human aging and degenerative conditions. The company's developmental pipeline features several promising cell-based therapeutic candidates: AGEX-BAT1: A cell therapy designed to manage various age-related metabolic disorders, including adult-onset Type II diabetes and obesity. AGEX-VASC1: A cell-based approach aimed at re-establishing vital vascular support in aged ischemic tissues, which could be relevant for conditions such as peripheral vascular disease and ischemic heart disease. Beyond cell therapies, AgeX is also exploring other modalities: Its primary drug candidate in the discovery phase is AGEX-iTR1547, a drug formulation focused on achieving scarless wound repair. For induced tissue regeneration, its leading biologic candidate is AGEX-iTR1550, which leverages gene delivery technology. Furthermore, AgeX maintains a research collaboration with the University of California at Irvine, jointly working to develop cellular therapies for various neurological disorders. Founded in 2017, AgeX Therapeutics, Inc. maintains its headquarters in Alameda, California.
株価
$11.10
最終同期: 2024-03-26
時価総額
$27.76M
変化(1日)
-11.90%
変化(1年)
0.00%
US
取引 AgeX Therapeutics, Inc. (AGE)

カテゴリー

AgeX Therapeutics, Inc.(AGE)の発行済株式数
August 2026 時点の発行済株式数 0
AgeX Therapeutics, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
AgeX Therapeutics, Inc.(AGE)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M -
US
396.00M -
US
62.19M -
NL
483.58M -
AU
- -
CH